Your browser doesn't support javascript.
loading
Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors.
Alserawan, Leticia; Mulet, Maria; Anguera, Geòrgia; Riudavets, Mariona; Zamora, Carlos; Osuna-Gómez, Rubén; Serra-López, Jorgina; Barba Joaquín, Andrés; Sullivan, Ivana; Majem, Margarita; Vidal, Silvia.
  • Alserawan L; Immunology-Inflammatory Diseases, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025 Barcelona, Spain.
  • Mulet M; Department of Immunology, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
  • Anguera G; Immunology-Inflammatory Diseases, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025 Barcelona, Spain.
  • Riudavets M; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
  • Zamora C; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
  • Osuna-Gómez R; Department of Pneumologie, Hôpital Cochin-APHP Centre, 75014 Paris, France.
  • Serra-López J; Immunology-Inflammatory Diseases, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025 Barcelona, Spain.
  • Barba Joaquín A; Immunology-Inflammatory Diseases, Biomedical Research Institute Sant Pau (IIB Sant Pau), 08025 Barcelona, Spain.
  • Sullivan I; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
  • Majem M; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
  • Vidal S; Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain.
Cancers (Basel) ; 16(9)2024 May 01.
Article en En | MEDLINE | ID: mdl-38730712
ABSTRACT
Immune checkpoint inhibitors (ICI) have the potential to trigger unpredictable immune-related adverse events (irAEs), which can be severe. The underlying mechanisms of these events are not fully understood. As PD-L1 is upregulated by IFN, the heightened immune activation resulting from PD-1/PD-L1 inhibition may enhance the IFN response, triggering the expression of IFN-inducible genes and contributing to irAE development and its severity. In this study, we investigated the interplay between irAEs and the expression of IFN-inducible chemokines and cytokines in 134 consecutive patients with solid tumours treated with PD-(L)1 inhibitors as monotherapy or in combination with chemotherapy or other immunotherapy agents. We compared the plasma levels of IFN-associated cytokines (CXCL9/10/11, IL-18, IL-10, IL-6 and TGFß) at various time points (at baseline, at the onset of irAE and previous to irAE onset) in three patient groups categorized by irAE development and severity patients with serious irAEs, mild irAEs and without irAEs after PD-(L)1 inhibitors. No differences were observed between groups at baseline. However, patients with serious irAEs exhibited significant increases in CXCL9/10/11, IL-18 and IL-10 levels at the onset of the irAE compared to baseline. A network analysis and correlation patterns highlighted a robust relationship among these chemokines and cytokines at serious-irAE onset. Combining all of the analysed proteins in a cluster analysis, we identified a subgroup of patients with a higher incidence of serious irAEs affecting different organs or systems. Finally, an ROC analysis and a decision tree model proposed IL-18 levels ≥ 807 pg/mL and TGFß levels ≤ 114 pg/mL as predictors for serious irAEs in 90% of cases. In conclusion, our study elucidates the dynamic changes in cytokine profiles associated with serious irAE development during treatment with PD-(L)1 inhibitors. The study's findings offer valuable insights into the intricate IFN-induced immune responses associated with irAEs and propose potential predictive markers for their severity.
Palabras clave